一分钟看懂
这是一项关于Esophageal Squamous Cell Carcinoma的I 期 / II 期研究，登记的药物或干预包括Pembrolizumab；I-DXd；Leucovorin；Levoleucovorin；5-Fluorouracil (5-FU)；Oxaliplatin；Sacituzumab tirumotecan；Rescue Medication，当前状态为招募中。登记地点显示中国合肥、北京、厦门、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pembrolizumab；I-DXd；Leucovorin；Levoleucovorin；5-Fluorouracil (5-FU)；Oxaliplatin；Sacituzumab tirumotecan；Rescue Medication · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Second Affiliated Hospital of Anhui Medical University ( Site 9511) · 合肥
- Beijing Cancer Hospital ( Site 9500) · 北京
- The First Affiliated Hospital of Xiamen University ( Site 9503) · 厦门
- Henan Cancer Hospital ( Site 9509) · 郑州
- Xuzhou Central Hospital ( Site 9512) · 徐州
- The First Affiliated Hospital of Nanchang University ( Site 9505) · 南昌
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic squamous cell carcinoma of the esophagus in first-line (1L) setting.
- * Has measurable disease per RECIST 1.1 as assessed by the local site. investigator or designee/radiology assessment and verified by BICR. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
- * Has had AEs due to previous anticancer therapies that have recovered to ≤Grade 1 or baseline. Endocrine-related AEs that are adequately treated with hormone replacement are elegible.
- * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).
- * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- * Has adequate organ function.
- Exclusion Criteria
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06780111；登记信息更新于 2026-09-17。